BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tai YT, Anderson KC. Targeting B-cell maturation antigen in multiple myeloma. Immunotherapy 2015;7:1187-99. [PMID: 26370838 DOI: 10.2217/imt.15.77] [Cited by in Crossref: 84] [Cited by in F6Publishing: 84] [Article Influence: 12.0] [Reference Citation Analysis]
Number Citing Articles
1 Goldstein RL, Goyos A, Li CM, Deegen P, Bogner P, Sternjak A, Thomas O, Klinger M, Wahl J, Friedrich M, Rattel B, Lamas E, Min X, Sudom A, Farshbaf M, Coxon A, Balazs M, Arvedson T. AMG 701 induces cytotoxicity of multiple myeloma cells and depletes plasma cells in cynomolgus monkeys. Blood Adv 2020;4:4180-94. [PMID: 32886754 DOI: 10.1182/bloodadvances.2020002565] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
2 Shah N, Aiello J, Avigan DE, Berdeja JG, Borrello IM, Chari A, Cohen AD, Ganapathi K, Gray L, Green D, Krishnan A, Lin Y, Manasanch E, Munshi NC, Nooka AK, Rapoport AP, Smith EL, Vij R, Dhodapkar M. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma. J Immunother Cancer 2020;8:e000734. [PMID: 32661116 DOI: 10.1136/jitc-2020-000734] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
3 Abrahams CL, Li X, Embry M, Yu A, Krimm S, Krueger S, Greenland NY, Wen KW, Jones C, DeAlmeida V, Solis WA, Matheny S, Kline T, Yam AY, Stafford R, Wiita AP, Hallam T, Lupher M, Molina A. Targeting CD74 in multiple myeloma with the novel, site-specific antibody-drug conjugate STRO-001. Oncotarget 2018;9:37700-14. [PMID: 30701025 DOI: 10.18632/oncotarget.26491] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
4 Bourbon E, Ghesquières H, Bachy E. CAR-T cells, from principle to clinical applications. Bulletin du Cancer 2021;108:S4-S17. [DOI: 10.1016/j.bulcan.2021.02.017] [Reference Citation Analysis]
5 An G, Acharya C, Feng X, Wen K, Zhong M, Zhang L, Munshi NC, Qiu L, Tai Y, Anderson KC. Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication. Blood 2016;128:1590-603. [DOI: 10.1182/blood-2016-03-707547] [Cited by in Crossref: 87] [Cited by in F6Publishing: 87] [Article Influence: 14.5] [Reference Citation Analysis]
6 Cho SF, Lin L, Xing L, Li Y, Wen K, Yu T, Hsieh PA, Munshi N, Wahl J, Matthes K, Friedrich M, Arvedson T, Anderson KC, Tai YT. The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models. Blood Adv 2020;4:4195-207. [PMID: 32898244 DOI: 10.1182/bloodadvances.2020002524] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 10.0] [Reference Citation Analysis]
7 Boyiadzis MM, Dhodapkar MV, Brentjens RJ, Kochenderfer JN, Neelapu SS, Maus MV, Porter DL, Maloney DG, Grupp SA, Mackall CL, June CH, Bishop MR. Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance. J Immunother Cancer 2018;6:137. [PMID: 30514386 DOI: 10.1186/s40425-018-0460-5] [Cited by in Crossref: 101] [Cited by in F6Publishing: 88] [Article Influence: 25.3] [Reference Citation Analysis]
8 Farooq AV, Degli Esposti S, Popat R, Thulasi P, Lonial S, Nooka AK, Jakubowiak A, Sborov D, Zaugg BE, Badros AZ, Jeng BH, Callander NS, Opalinska J, Baron J, Piontek T, Byrne J, Gupta I, Colby K. Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study. Ophthalmol Ther 2020;9:889-911. [PMID: 32712806 DOI: 10.1007/s40123-020-00280-8] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 14.0] [Reference Citation Analysis]
9 Cho SF, Lin L, Xing L, Li Y, Yu T, Anderson KC, Tai YT. BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma. Cancers (Basel) 2020;12:E1473. [PMID: 32516895 DOI: 10.3390/cancers12061473] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
10 Joseph NS, Tai YT, Anderson KC, Lonial S. Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor. Clin Pharmacol 2021;13:169-80. [PMID: 34434061 DOI: 10.2147/CPAA.S288840] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Zanwar S, Nandakumar B, Kumar S. Immune-based therapies in the management of multiple myeloma. Blood Cancer J 2020;10:84. [PMID: 32829378 DOI: 10.1038/s41408-020-00350-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
12 Pahl A, Lutz C, Hechler T. Amanitins and their development as a payload for antibody-drug conjugates. Drug Discov Today Technol 2018;30:85-9. [PMID: 30553524 DOI: 10.1016/j.ddtec.2018.08.005] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 8.0] [Reference Citation Analysis]
13 Haber L, Olson K, Kelly MP, Crawford A, DiLillo DJ, Tavaré R, Ullman E, Mao S, Canova L, Sineshchekova O, Finney J, Pawashe A, Patel S, McKay R, Rizvi S, Damko E, Chiu D, Vazzana K, Ram P, Mohrs K, D'Orvilliers A, Xiao J, Makonnen S, Hickey C, Arnold C, Giurleo J, Chen YP, Thwaites C, Dudgeon D, Bray K, Rafique A, Huang T, Delfino F, Hermann A, Kirshner JR, Retter MW, Babb R, MacDonald D, Chen G, Olson WC, Thurston G, Davis S, Lin JC, Smith E. Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning. Sci Rep 2021;11:14397. [PMID: 34257348 DOI: 10.1038/s41598-021-93842-0] [Reference Citation Analysis]
14 Pereira RB, Evdokimov NM, Lefranc F, Valentão P, Kornienko A, Pereira DM, Andrade PB, Gomes NGM. Marine-Derived Anticancer Agents: Clinical Benefits, Innovative Mechanisms, and New Targets. Mar Drugs 2019;17:E329. [PMID: 31159480 DOI: 10.3390/md17060329] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 11.7] [Reference Citation Analysis]
15 Schuh E, Musumeci A, Thaler FS, Laurent S, Ellwart JW, Hohlfeld R, Krug A, Meinl E. Human Plasmacytoid Dendritic Cells Display and Shed B Cell Maturation Antigen upon TLR Engagement. J I 2017;198:3081-8. [DOI: 10.4049/jimmunol.1601746] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 5.2] [Reference Citation Analysis]
16 Tai YT, Anderson KC. B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma. Expert Opin Biol Ther 2019;19:1143-56. [PMID: 31277554 DOI: 10.1080/14712598.2019.1641196] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 8.3] [Reference Citation Analysis]
17 Kocoglu M, Badros A. The Role of Immunotherapy in Multiple Myeloma. Pharmaceuticals (Basel) 2016;9:E3. [PMID: 26784207 DOI: 10.3390/ph9010003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
18 Nobari ST, Nojadeh JN, Talebi M. B-cell maturation antigen targeting strategies in multiple myeloma treatment, advantages and disadvantages. J Transl Med 2022;20:82. [PMID: 35144648 DOI: 10.1186/s12967-022-03285-y] [Reference Citation Analysis]
19 Hipp S, Tai YT, Blanset D, Deegen P, Wahl J, Thomas O, Rattel B, Adam PJ, Anderson KC, Friedrich M. A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo. Leukemia 2017;31:1743-51. [PMID: 28025583 DOI: 10.1038/leu.2016.388] [Cited by in Crossref: 107] [Cited by in F6Publishing: 103] [Article Influence: 17.8] [Reference Citation Analysis]
20 Li C, Cao W, Que Y, Wang Q, Xiao Y, Gu C, Wang D, Wang J, Jiang L, Xu H, Xu J, Zhou X, Hong Z, Wang N, Huang L, Zhang S, Chen L, Mao X, Xiao M, Zhang W, Meng L, Cao Y, Zhang T, Li J, Zhou J. A phase I study of anti-BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia. Clin Transl Med 2021;11:e346. [PMID: 33784005 DOI: 10.1002/ctm2.346] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Abramson HN. Immunotherapy of Multiple Myeloma: Promise and Challenges. Immunotargets Ther 2021;10:343-71. [PMID: 34527606 DOI: 10.2147/ITT.S306103] [Reference Citation Analysis]
22 Wu L, Huang Y, Sienkiewicz J, Sun J, Guiang L, Li F, Yang L, Golubovskaya V. Bispecific BCMA-CD3 Antibodies Block Multiple Myeloma Tumor Growth. Cancers 2022;14:2518. [DOI: 10.3390/cancers14102518] [Reference Citation Analysis]
23 Prawitz T, Popat R, Suvannasankha A, Sarri G, Hughes R, Wang F, Hogea C, Ferrante SA, Gorsh B, Willson J, Kapetanakis V. DREAMM-2: Indirect Comparisons of Belantamab Mafodotin vs. Selinexor + Dexamethasone and Standard of Care Treatments in Relapsed/Refractory Multiple Myeloma. Adv Ther 2021;38:5501-18. [PMID: 34561812 DOI: 10.1007/s12325-021-01884-7] [Reference Citation Analysis]
24 An N, Hou YN, Zhang QX, Li T, Zhang QL, Fang C, Chen H, Lee HC, Zhao YJ, Du X. Anti-Multiple Myeloma Activity of Nanobody-Based Anti-CD38 Chimeric Antigen Receptor T Cells. Mol Pharm 2018;15:4577-88. [PMID: 30185037 DOI: 10.1021/acs.molpharmaceut.8b00584] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 6.5] [Reference Citation Analysis]
25 Zagouri F, Terpos E, Kastritis E, Dimopoulos MA. Emerging antibodies for the treatment of multiple myeloma. Expert Opinion on Emerging Drugs 2016;21:225-37. [DOI: 10.1080/14728214.2016.1186644] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
26 Wang B, Rajeeve S, Madduri D. Chimeric Antigen Receptor T-Cell Therapeutics for Multiple Myeloma: Moving Into the Spotlight. Cancer J 2021;27:205-12. [PMID: 34549909 DOI: 10.1097/PPO.0000000000000525] [Reference Citation Analysis]
27 Lejeune M, Köse MC, Duray E, Einsele H, Beguin Y, Caers J. Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies. Front Immunol 2020;11:762. [PMID: 32457743 DOI: 10.3389/fimmu.2020.00762] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
28 Ghosh A, Mailankody S, Giralt SA, Landgren CO, Smith EL, Brentjens RJ. CAR T cell therapy for multiple myeloma: where are we now and where are we headed? Leuk Lymphoma 2018;59:2056-67. [PMID: 29105517 DOI: 10.1080/10428194.2017.1393668] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 6.2] [Reference Citation Analysis]
29 Baljevic M, Holstein SA. Present and Future of Immunotherapy in the Management of Multiple Myeloma. J Oncol Pract 2018;14:403-10. [PMID: 29996070 DOI: 10.1200/JOP.18.00111] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
30 Lin L, Cho SF, Xing L, Wen K, Li Y, Yu T, Hsieh PA, Chen H, Kurtoglu M, Zhang Y, Andrew Stewart C, Munshi N, Anderson KC, Tai YT. Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma. Leukemia 2021;35:752-63. [PMID: 32632095 DOI: 10.1038/s41375-020-0951-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
31 Xing L, Lin L, Yu T, Li Y, Cho SF, Liu J, Wen K, Hsieh PA, Kinneer K, Munshi N, Anderson KC, Tai YT. A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma. Leukemia 2020;34:2150-62. [PMID: 32060401 DOI: 10.1038/s41375-020-0745-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 9.5] [Reference Citation Analysis]
32 Joubert N, Beck A, Dumontet C, Denevault-Sabourin C. Antibody-Drug Conjugates: The Last Decade. Pharmaceuticals (Basel) 2020;13:E245. [PMID: 32937862 DOI: 10.3390/ph13090245] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 23.0] [Reference Citation Analysis]
33 Tai YT, Acharya C, An G, Moschetta M, Zhong MY, Feng X, Cea M, Cagnetta A, Wen K, van Eenennaam H, van Elsas A, Qiu L, Richardson P, Munshi N, Anderson KC. APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment. Blood 2016;127:3225-36. [PMID: 27127303 DOI: 10.1182/blood-2016-01-691162] [Cited by in Crossref: 141] [Cited by in F6Publishing: 129] [Article Influence: 23.5] [Reference Citation Analysis]
34 Rotolo A, Karadimitris A, Ruella M. Building upon the success of CART19: chimeric antigen receptor T cells for hematologic malignancies. Leuk Lymphoma 2018;59:2040-55. [PMID: 29165008 DOI: 10.1080/10428194.2017.1403024] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
35 Devarakonda S, Cottini F, Bumma N, Khan A, Sharma N, Chaudhry M, Benson D, Rosko A, Efebera Y. Multiple Myeloma: Clinical Updates from the American Society of Clinical Oncology Annual Scientific Symposium 2020. J Clin Med 2020;9:E3626. [PMID: 33187184 DOI: 10.3390/jcm9113626] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
36 Pawlyn C, Morgan GJ. Evolutionary biology of high-risk multiple myeloma. Nat Rev Cancer 2017;17:543-56. [PMID: 28835722 DOI: 10.1038/nrc.2017.63] [Cited by in Crossref: 98] [Cited by in F6Publishing: 94] [Article Influence: 19.6] [Reference Citation Analysis]
37 Mané-Damas M, Molenaar PC, Ulrichts P, Marcuse F, De Baets MH, Martinez-Martinez P, Losen M. Novel treatment strategies for acetylcholine receptor antibody-positive myasthenia gravis and related disorders. Autoimmun Rev 2022;:103104. [PMID: 35452851 DOI: 10.1016/j.autrev.2022.103104] [Reference Citation Analysis]
38 Wang H, Kaur G, Sankin AI, Chen F, Guan F, Zang X. Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies. J Hematol Oncol. 2019;12:59. [PMID: 31186046 DOI: 10.1186/s13045-019-0746-1] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 15.0] [Reference Citation Analysis]
39 Shabgah AG, Shariati-Sarabi Z, Tavakkol-Afshari J, Mohammadi M. The role of BAFF and APRIL in rheumatoid arthritis. J Cell Physiol 2019;234:17050-63. [PMID: 30941763 DOI: 10.1002/jcp.28445] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 6.7] [Reference Citation Analysis]
40 Ng YY, Du Z, Zhang X, Chng WJ, Wang S. CXCR4 and anti-BCMA CAR co-modified natural killer cells suppress multiple myeloma progression in a xenograft mouse model. Cancer Gene Ther 2021. [PMID: 34471234 DOI: 10.1038/s41417-021-00365-x] [Reference Citation Analysis]
41 Mostafa Kamel Y. CAR-T Therapy, the End of a Chapter or the Beginning of a New One? Cancers (Basel) 2021;13:853. [PMID: 33670515 DOI: 10.3390/cancers13040853] [Reference Citation Analysis]
42 Becnel MR, Lee HC. The role of belantamab mafodotin for patients with relapsed and/or refractory multiple myeloma. Ther Adv Hematol 2020;11:2040620720979813. [PMID: 33403093 DOI: 10.1177/2040620720979813] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
43 Gay F, Engelhardt M, Terpos E, Wäsch R, Giaccone L, Auner HW, Caers J, Gramatzki M, van de Donk N, Oliva S, Zamagni E, Garderet L, Straka C, Hajek R, Ludwig H, Einsele H, Dimopoulos M, Boccadoro M, Kröger N, Cavo M, Goldschmidt H, Bruno B, Sonneveld P. From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives. Haematologica 2018;103:197-211. [PMID: 29217780 DOI: 10.3324/haematol.2017.174573] [Cited by in Crossref: 78] [Cited by in F6Publishing: 66] [Article Influence: 15.6] [Reference Citation Analysis]
44 Friedman KM, Garrett TE, Evans JW, Horton HM, Latimer HJ, Seidel SL, Horvath CJ, Morgan RA. Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells. Hum Gene Ther 2018;29:585-601. [PMID: 29641319 DOI: 10.1089/hum.2018.001] [Cited by in Crossref: 80] [Cited by in F6Publishing: 74] [Article Influence: 26.7] [Reference Citation Analysis]
45 Abramson HN. Monoclonal Antibodies for the Treatment of Multiple Myeloma: An Update. Int J Mol Sci 2018;19:E3924. [PMID: 30544512 DOI: 10.3390/ijms19123924] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 6.5] [Reference Citation Analysis]
46 Rathi C, Collins J, Struemper H, Opalinska J, Jewell RC, Ferron-Brady G. Population pharmacokinetics of belantamab mafodotin, a BCMA-targeting agent in patients with relapsed/refractory multiple myeloma. CPT Pharmacometrics Syst Pharmacol 2021;10:851-63. [PMID: 34076364 DOI: 10.1002/psp4.12660] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
47 Golubovskaya V, Zhou H, Li F, Berahovich R, Sun J, Valentine M, Xu S, Harto H, Sienkiewicz J, Huang Y, Wu L. Novel CS1 CAR-T Cells and Bispecific CS1-BCMA CAR-T Cells Effectively Target Multiple Myeloma. Biomedicines 2021;9:1422. [PMID: 34680541 DOI: 10.3390/biomedicines9101422] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Feinberg D, Paul B, Kang Y. The promise of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma. Cell Immunol 2019;345:103964. [PMID: 31492448 DOI: 10.1016/j.cellimm.2019.103964] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
49 Deng H, Liu M, Yuan T, Zhang H, Cui R, Li J, Yuan J, Wang X, Wang Y, Deng Q. Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease. Front Immunol 2021;12:720571. [PMID: 34421924 DOI: 10.3389/fimmu.2021.720571] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
50 Meir J, Abid MA, Abid MB. State of the CAR-T: Risk of Infections with Chimeric Antigen Receptor T-Cell Therapy and Determinants of SARS-CoV-2 Vaccine Responses. Transplant Cell Ther 2021:S2666-6367(21)01258-6. [PMID: 34587552 DOI: 10.1016/j.jtct.2021.09.016] [Reference Citation Analysis]
51 Richardson PG, Lee HC, Abdallah AO, Cohen AD, Kapoor P, Voorhees PM, Hoos A, Wang K, Baron J, Piontek T, Byrne J, Richmond S, Jewell RC, Opalinska J, Gupta I, Lonial S. Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study. Blood Cancer J 2020;10:106. [PMID: 33097687 DOI: 10.1038/s41408-020-00369-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
52 Tan CR, Shah UA. Targeting BCMA in Multiple Myeloma. Curr Hematol Malig Rep 2021;16:367-83. [PMID: 34432234 DOI: 10.1007/s11899-021-00639-z] [Reference Citation Analysis]
53 Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, Liedtke M, Rosenblatt J, Maus MV, Turka A, Lam LP, Morgan RA, Friedman K, Massaro M, Wang J, Russotti G, Yang Z, Campbell T, Hege K, Petrocca F, Quigley MT, Munshi N, Kochenderfer JN. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2019;380:1726-1737. [PMID: 31042825 DOI: 10.1056/nejmoa1817226] [Cited by in Crossref: 507] [Cited by in F6Publishing: 280] [Article Influence: 169.0] [Reference Citation Analysis]
54 Atrash S, Moyo TK. A Review of Chimeric Antigen Receptor T-Cell Therapy for Myeloma and Lymphoma. Onco Targets Ther 2021;14:2185-201. [PMID: 33814917 DOI: 10.2147/OTT.S242018] [Reference Citation Analysis]
55 Fang Y, Hou J. Immunotherapeutic strategies targeting B cell maturation antigen in multiple myeloma. Mil Med Res 2021;8:9. [PMID: 33504363 DOI: 10.1186/s40779-021-00302-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
56 Cho SF, Anderson KC, Tai YT. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy. Front Immunol 2018;9:1821. [PMID: 30147690 DOI: 10.3389/fimmu.2018.01821] [Cited by in Crossref: 108] [Cited by in F6Publishing: 102] [Article Influence: 27.0] [Reference Citation Analysis]
57 Tai YT, Lin L, Xing L, Cho SF, Yu T, Acharya C, Wen K, Hsieh PA, Dulos J, van Elsas A, Munshi N, Richardson P, Anderson KC. APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications. Leukemia 2019;33:426-38. [PMID: 30135465 DOI: 10.1038/s41375-018-0242-6] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 7.5] [Reference Citation Analysis]
58 Bozic B, Rutner J, Zheng C, Ruckser R, Selimi F, Racz K, Köcher M, Tatzreiter G, Sebesta C. Advances in the Treatment of Relapsed and Refractory Multiple Myeloma in Patients with Renal Insufficiency: Novel Agents, Immunotherapies and Beyond. Cancers (Basel) 2021;13:5036. [PMID: 34680184 DOI: 10.3390/cancers13205036] [Reference Citation Analysis]
59 Bath NM, Ding X, Verhoven BM, Wilson NA, Coons L, Sukhwal A, Zhong W, Redfield Iii RR. Autoantibody production significantly decreased with APRIL/BLyS blockade in murine chronic rejection kidney transplant model. PLoS One 2019;14:e0223889. [PMID: 31647850 DOI: 10.1371/journal.pone.0223889] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
60 Nikolaou A, Ambavane A, Shah A, Ma W, Tosh J, Kapetanakis V, Willson J, Wang F, Hogea C, Gorsh B, Gutierrez B, Sapra S, Suvannasankha A, Samyshkin Y. Belantamab mafodotin for the treatment of relapsed/refractory multiple myeloma in heavily pretreated patients: a US cost-effectiveness analysis. Expert Rev Hematol 2021;:1-9. [PMID: 34465265 DOI: 10.1080/17474086.2021.1970522] [Reference Citation Analysis]
61 Gambella A, Barreca A, Osella-Abate S, Bottasso E, Giarin MM, Papotti M, Biancone L, Metovic J, Collemi G, Cassoni P, Bertero L. Caveolin-1 in Kidney Chronic Antibody-Mediated Rejection: An Integrated Immunohistochemical and Transcriptomic Analysis Based on the Banff Human Organ Transplant (B-HOT) Gene Panel. Biomedicines 2021;9:1318. [PMID: 34680435 DOI: 10.3390/biomedicines9101318] [Reference Citation Analysis]
62 Safarzadeh Kozani P, Naseri A, Mirarefin SMJ, Salem F, Nikbakht M, Evazi Bakhshi S, Safarzadeh Kozani P. Nanobody-based CAR-T cells for cancer immunotherapy. Biomark Res 2022;10:24. [PMID: 35468841 DOI: 10.1186/s40364-022-00371-7] [Reference Citation Analysis]
63 Ma T, Shi J, Liu H. Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma. Ann Hematol 2019;98:813-22. [PMID: 30693373 DOI: 10.1007/s00277-018-03592-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
64 Ferron-Brady G, Rathi C, Collins J, Struemper H, Opalinska J, Visser S, Jewell RC. Exposure-Response Analyses for Therapeutic Dose Selection of Belantamab Mafodotin in Patients With Relapsed/Refractory Multiple Myeloma. Clin Pharmacol Ther 2021;110:1282-92. [PMID: 34468979 DOI: 10.1002/cpt.2409] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
65 Raje NS, Moreau P, Terpos E, Benboubker L, Grząśko N, Holstein SA, Oriol A, Huang SY, Beksac M, Kuliczkowski K, Tai DF, Wooldridge JE, Conti I, Kaiser CJ, Nguyen TS, Cronier DM, Palumbo A. Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma. Br J Haematol 2017;176:783-95. [PMID: 28005265 DOI: 10.1111/bjh.14483] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 4.5] [Reference Citation Analysis]
66 Swan D, Routledge D, Harrison S. The evolving status of immunotherapies in multiple myeloma: the future role of bispecific antibodies. Br J Haematol 2021. [PMID: 34472091 DOI: 10.1111/bjh.17805] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
67 Lohr JG, Kim S, Gould J, Knoechel B, Drier Y, Cotton MJ, Gray D, Birrer N, Wong B, Ha G, Zhang CZ, Guo G, Meyerson M, Yee AJ, Boehm JS, Raje N, Golub TR. Genetic interrogation of circulating multiple myeloma cells at single-cell resolution. Sci Transl Med 2016;8:363ra147. [PMID: 27807282 DOI: 10.1126/scitranslmed.aac7037] [Cited by in Crossref: 76] [Cited by in F6Publishing: 73] [Article Influence: 15.2] [Reference Citation Analysis]
68 Dostert C, Grusdat M, Letellier E, Brenner D. The TNF Family of Ligands and Receptors: Communication Modules in the Immune System and Beyond. Physiological Reviews 2019;99:115-60. [DOI: 10.1152/physrev.00045.2017] [Cited by in Crossref: 76] [Cited by in F6Publishing: 86] [Article Influence: 25.3] [Reference Citation Analysis]
69 Shi L, Qin X, Wang H, Xia Y, Li Y, Chen X, Shang L, Tai YT, Feng X, Acharya P, Acharya C, Xu Y, Deng S, Hao M, Zou D, Zhao Y, Ru K, Qiu L, An G. Elevated neutrophil-to-lymphocyte ratio and monocyte-to-lymphocyte ratio and decreased platelet-to-lymphocyte ratio are associated with poor prognosis in multiple myeloma. Oncotarget 2017;8:18792-801. [PMID: 27852046 DOI: 10.18632/oncotarget.13320] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 7.4] [Reference Citation Analysis]
70 Zhong MJ, Xu YX, Xing HY, Tang KJ, Tian Z, Rao Q, Wang M, Wang JX. [Targeting BCMA in multiple myeloma using chimeric antigen receptor-engineered T cells]. Zhonghua Xue Ye Xue Za Zhi 2019;40:804-11. [PMID: 31775477 DOI: 10.3760/cma.j.issn.0253-2727.2019.10.002] [Reference Citation Analysis]
71 Rotolo A, Caputo V, Karadimitris A. The prospects and promise of chimeric antigen receptor immunotherapy in multiple myeloma. Br J Haematol 2016;173:350-64. [DOI: 10.1111/bjh.13976] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
72 Cho SF, Xing L, Anderson KC, Tai YT. Promising Antigens for the New Frontier of Targeted Immunotherapy in Multiple Myeloma. Cancers (Basel) 2021;13:6136. [PMID: 34885245 DOI: 10.3390/cancers13236136] [Reference Citation Analysis]
73 Dogan A, Siegel D, Tran N, Fu A, Fowler J, Belani R, Landgren O. B-cell maturation antigen expression across hematologic cancers: a systematic literature review. Blood Cancer J 2020;10:73. [PMID: 32606424 DOI: 10.1038/s41408-020-0337-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
74 McMillan A, Warcel D, Popat R. Antibody-drug conjugates for multiple myeloma. Expert Opin Biol Ther 2021;21:889-901. [PMID: 32729730 DOI: 10.1080/14712598.2020.1802422] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
75 Cho SF, Anderson KC, Tai YT. BCMA CAR T-cell therapy arrives for multiple myeloma: a reality. Ann Transl Med 2018;6:S93. [PMID: 30740414 DOI: 10.21037/atm.2018.11.14] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
76 Mikkilineni L, Kochenderfer JN. CAR T cell therapies for patients with multiple myeloma. Nat Rev Clin Oncol 2021;18:71-84. [PMID: 32978608 DOI: 10.1038/s41571-020-0427-6] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 13.0] [Reference Citation Analysis]
77 Hosoya H, Sidana S. Antibody-Based Treatment Approaches in Multiple Myeloma. Curr Hematol Malig Rep 2021;16:183-91. [PMID: 33730360 DOI: 10.1007/s11899-021-00624-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
78 Lonial S, Nooka AK, Thulasi P, Badros AZ, Jeng BH, Callander NS, Potter HA, Sborov D, Zaugg BE, Popat R, Degli Esposti S, Byrne J, Opalinska J, Baron J, Piontek T, Gupta I, Dana R, Farooq AV, Colby K, Jakubowiak A. Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM). Blood Cancer J 2021;11:103. [PMID: 34039952 DOI: 10.1038/s41408-021-00494-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
79 Demel I, Bago JR, Hajek R, Jelinek T. Focus on monoclonal antibodies targeting B-cell maturation antigen (BCMA) in multiple myeloma: update 2021. Br J Haematol 2021;193:705-22. [PMID: 33216972 DOI: 10.1111/bjh.17235] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
80 Storti P, Costa F, Marchica V, Burroughs-Garcia J, Dalla Palma B, Toscani D, Eufemiese RA, Giuliani N. Novel Approaches to Improve Myeloma Cell Killing by Monoclonal Antibodies. J Clin Med 2020;9:E2864. [PMID: 32899714 DOI: 10.3390/jcm9092864] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
81 Marella M, Yao X, Carreira V, Bustamante MF, Clark HB, Jackson CC, Zudaire E, Schecter JM, Glover TD, Shenton J, Cornax I. Comprehensive BCMA Expression Profiling in Adult Normal Human Brain Suggests a Low Risk of On-target Neurotoxicity in BCMA-targeting Multiple Myeloma Therapy. J Histochem Cytochem 2022;:221554221079579. [PMID: 35193424 DOI: 10.1369/00221554221079579] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
82 Wu C, Zhang L, Brockman QR, Zhan F, Chen L. Chimeric antigen receptor T cell therapies for multiple myeloma. J Hematol Oncol 2019;12:120. [PMID: 31752943 DOI: 10.1186/s13045-019-0823-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
83 Townsend MH, Shrestha G, Robison RA, O'Neill KL. The expansion of targetable biomarkers for CAR T cell therapy. J Exp Clin Cancer Res 2018;37:163. [PMID: 30031396 DOI: 10.1186/s13046-018-0817-0] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 10.5] [Reference Citation Analysis]
84 Wei X, Calvo-Vidal MN, Chen S, Wu G, Revuelta MV, Sun J, Zhang J, Walsh MF, Nichols KE, Joseph V, Snyder C, Vachon CM, McKay JD, Wang SP, Jayabalan DS, Jacobs LM, Becirovic D, Waller RG, Artomov M, Viale A, Patel J, Phillip J, Chen-Kiang S, Curtin K, Salama M, Atanackovic D, Niesvizky R, Landgren O, Slager SL, Godley LA, Churpek J, Garber JE, Anderson KC, Daly MJ, Roeder RG, Dumontet C, Lynch HT, Mullighan CG, Camp NJ, Offit K, Klein RJ, Yu H, Cerchietti L, Lipkin SM. Germline Lysine-Specific Demethylase 1 (LSD1/KDM1A) Mutations Confer Susceptibility to Multiple Myeloma. Cancer Res 2018;78:2747-59. [PMID: 29559475 DOI: 10.1158/0008-5472.CAN-17-1900] [Cited by in Crossref: 28] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
85 Ivica NA, Young CM. Tracking the CAR-T Revolution: Analysis of Clinical Trials of CAR-T and TCR-T Therapies for the Treatment of Cancer (1997-2020). Healthcare (Basel) 2021;9:1062. [PMID: 34442199 DOI: 10.3390/healthcare9081062] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
86 Perez-Amill L, Marzal B, Urbano-Ispizua A, Juan M, Martín-Antonio B. CAR-T Cell Therapy: A Door Is Open to Find Innumerable Possibilities of Treatments for Cancer Patients. Turk J Haematol 2018;35:217-28. [PMID: 30185400 DOI: 10.4274/tjh.2018.0196] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
87 Nadeem O, Tai YT, Anderson KC. Immunotherapeutic and Targeted Approaches in Multiple Myeloma. Immunotargets Ther 2020;9:201-15. [PMID: 33117743 DOI: 10.2147/ITT.S240886] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
88 Abramson HN. B-Cell Maturation Antigen (BCMA) as a Target for New Drug Development in Relapsed and/or Refractory Multiple Myeloma. Int J Mol Sci 2020;21:E5192. [PMID: 32707894 DOI: 10.3390/ijms21155192] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
89 Marofi F, Tahmasebi S, Rahman HS, Kaigorodov D, Markov A, Yumashev AV, Shomali N, Chartrand MS, Pathak Y, Mohammed RN, Jarahian M, Motavalli R, Motavalli Khiavi F. Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism. Stem Cell Res Ther 2021;12:217. [PMID: 33781320 DOI: 10.1186/s13287-021-02283-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
90 Hosny M, Verkleij CPM, van der Schans J, Frerichs KA, Mutis T, Zweegman S, van de Donk NWCJ. Current State of the Art and Prospects of T Cell-Redirecting Bispecific Antibodies in Multiple Myeloma. J Clin Med 2021;10:4593. [PMID: 34640611 DOI: 10.3390/jcm10194593] [Reference Citation Analysis]
91 Rossi C, Chrétien M, Casasnovas R. Antibody–Drug Conjugates for the Treatment of Hematological Malignancies: A Comprehensive Review. Targ Oncol 2018;13:287-308. [DOI: 10.1007/s11523-018-0558-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
92 Caraccio C, Krishna S, Phillips DJ, Schürch CM. Bispecific Antibodies for Multiple Myeloma: A Review of Targets, Drugs, Clinical Trials, and Future Directions. Front Immunol 2020;11:501. [PMID: 32391000 DOI: 10.3389/fimmu.2020.00501] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 15.0] [Reference Citation Analysis]
93 Deng J, Park D, Wang M, Nooka A, Deng Q, Matulis S, Kaufman J, Lonial S, Boise LH, Galipeau J, Deng X. BCL2-BH4 antagonist BDA-366 suppresses human myeloma growth. Oncotarget 2016;7:27753-63. [PMID: 27049723 DOI: 10.18632/oncotarget.8513] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
94 Tong JTW, Harris PWR, Brimble MA, Kavianinia I. An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy. Molecules 2021;26:5847. [PMID: 34641391 DOI: 10.3390/molecules26195847] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
95 Chen KH, Wada M, Pinz KG, Liu H, Shuai X, Chen X, Yan LE, Petrov JC, Salman H, Senzel L, Leung ELH, Jiang X, Ma Y. A compound chimeric antigen receptor strategy for targeting multiple myeloma. Leukemia 2018;32:402-12. [PMID: 28951562 DOI: 10.1038/leu.2017.302] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 9.0] [Reference Citation Analysis]
96 Wolska-Washer A, Robak T. Safety and Tolerability of Antibody-Drug Conjugates in Cancer. Drug Saf 2019;42:295-314. [PMID: 30649747 DOI: 10.1007/s40264-018-0775-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 9.7] [Reference Citation Analysis]